Different AAV vector-mediated and ASO strategies aiming at silencing SOD1 or C9orf72 as a therapeutic approach in familial ALS are currently being developed and tested in pre-clinical studies (Cappella et al., 2019; Amado and Davidson, 2021). Here, C9orf72 is linked to amyotrophic lateral sclerosis.